Multiple Myeloma Clinical Trials in Ann Arbor, Michigan

8 studies are recruiting for multiple myeloma in Ann Arbor, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Collection of Tissue Samples for Cancer Research

   Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research …

   Stage

   Not phased

   Ages

   0 and older

   Site

   University of Michigan Ann Arbor, Ann Arbor, Michigan

   Locations

   17 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT00900198 on ClinicalTrials.gov

2. A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

   Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Michigan Health System - Ann Arbor /ID# 271536, Ann Arbor, Michigan

   Locations

   50 in total

   Run by

   AbbVie

   See if you can join NCT06953960 on ClinicalTrials.gov

3. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Trinity Health Ann Arbor Hospital, Ann Arbor, Michigan

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

4. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

   The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Michigan, Ann Arbor, Michigan

   Locations

   270 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05552222 on ClinicalTrials.gov

5. AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

   This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Ann Arbor, Michigan

   Locations

   43 in total

   Run by

   AstraZeneca

   See if you can join NCT06106945 on ClinicalTrials.gov

6. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

   This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   University of Michigan, Ann Arbor, Michigan

   Locations

   33 in total

   Run by

   Pfizer

   See if you can join NCT06057402 on ClinicalTrials.gov

7. A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

   The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   GSK Investigational Site, Ann Arbor, Michigan

   Locations

   181 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06679101 on ClinicalTrials.gov

8. Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

   The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research que…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   C. S. Mott_University of Michigan, Ann Arbor, Michigan

   Locations

   40 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT03761108 on ClinicalTrials.gov